Full Press Release Details
A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study
Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology
International Symposium
REDWOOD CITY, Calif. June 20, 2012 A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty
pharmaceutical company, today announced that the Company will present patient-satisfaction data from its Phase 3 trial of APF530 at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology
(MASCC/ISOO) International Symposium. The MASCC/ISOO 2012 International Symposium focuses on the clinical management of supportive care in oncology and will be held in New York City June 28 30. APF530 is the Company s lead product
candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).
details are as follows:
| Title: | Patient satisfaction with control of emesis following chemotherapy: comparison of APF530, a subcutaneous extended-release formulation of granisetron versus intravenous palonosetron | |
| Authors: | Rebecca Clark-Snow, Veena Charu, Nashat Gabrail, Ronald Yanagihara, Martin Rosenberg, Erin O Boyle, John Barr | |
| Abstract No.: | 1109 | |
| Presentation: | June 29, 2012, Poster Session II |
The full abstract is available on the MASCC/ISOO website, here.
Pharma s lead product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company s
proprietary Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five
days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by
physicians based on a well-established record of safety and efficacy.
A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer polymer-based drug delivery technology. The Company s primary focus is on its lead product, APF530, for the
prevention of CINV. A.P. Pharma
received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its
bioerodible, injectable and implantable delivery systems. For further information, please visit the Company s web site at www.appharma.com.
Forward-looking Statements
This news release contains forward-looking
statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with capital resources and liquidity, timely development and
regulatory approval of product candidates, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company s filings
with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.
Email: mrice@lifesciadvisors.com
John B. Whelan, President and Chief Executive Officer
Office Phone: 650-366-2626